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Abstract  Diabetes  mellitus  (DM)  is  a  metabolic  disorder  that  causes  chronic  hyperglycemia
with disturbances  in the  metabolism  of  carbohydrates,  fats  and  proteins,  and  alterations  in
microcirculation.  We  evaluate  the criteria  for  the  interpretation  of  the  oral  glucose  tolerance
test (OGTT)  in the  Hospital  Nacional  Docente  Madre-Nin˜o  ‘‘San  Bartolomé’’  in Lima,  Peru,  and
determine  the  percentages  of  pre-diabetic  patients,  diabetics  that  should  not  be included  in the
test, and  those  with  alterations  in  their  glucose  curve  during  the  biochemical  determinations.
To this purpose,  a  non-experimental,  prospective  cross-sectional  analytic  study  was
performed  in 1271  patients,  included  in  the  study  to  comply  with  the  guidelines  and  recommen-
dations  of  the  ADA  and the  CLSI  POCT12-A3  guide,  which  were  processed  in  the Biochemical
Autoanalyzer  Biosystems  A25.  Data  analysis  was  performed  using  SPSS  version  20.0  statistical
analyzer,  and  respecting  ethical  diabetics.
The  main  results  are 1.97%  diabetic  and  13.85%  pre-diabetic.  The  LJ phenomenon  occurred
with 6.45%  (alteration  in  glucose  curve  after  oral  load  decreases  plasma  glucose  concentration
determination  after  60  min  and  returns  at relatively  higher  than  the  basal  concentration  levels
at 180  min)  and  5.19%  were  poorly  studied,  including  a  >110  mg/dl  baseline  (p = <0.05).  We
determined  a  high  rate  of  pre-diabetic  patients  and a  reduced  rate  of  diabetes  coincident  with
Qiao et  al.  We  highlight  the  usefulness  of  the  OGTT,  which  must  be  rigorously  evaluated,  and
reaffirm the importance  of  the  LJ  phenomenon  as  it  may  interfere  with  the  final  results  of
unsolved events,  and  evidence  the  importance  of  interindividual  biological  variability.
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Introduction
Diabetes  mellitus  (DM)  is  a metabolic  disorder  that  is  a
consequence  of  the deficiency  in the secretion  of  insulin,
in  the  effectiveness  of  its  actions,  or  both.  It  is one  of
the  most  prevalent  chronic  diseases  in  the world.  It con-
stitutes  a  public  health  problem  due to  the progressive
increase  of  its  incidence,  to  the point  where  it is  consid-
ered  an  epidemic.1 Chronic  hyperglycemia  with  disturbances
in  the  metabolism  of carbohydrates,  fats  and  proteins,  and
alterations  in microcirculation  are all  consequences  of  this
disorder.  Current  DM  classification  according  to  the Ameri-
can  Diabetes  Association  --  ADA  --  is  shown  in Table  1.
About  63%  of the  57  million  deaths  in the world  in 2008
were  caused  by  a  non-transmissible  chronic  disease,  includ-
ing  diabetes  mellitus;  thus, 80%  of  these deaths  occurred
in  low  and  medium-income  countries.2 By the year  2000,
about  171  million  people  suffered  from  DM  around  the world,
and  this  number  is  estimated  to  go up  to  336 million  by  the
year  2030.3,4 On the  other  hand,  approximately  197  million
people  worldwide  suffer  from  glucose  intolerance  --  pre-
diabetic  patients,  which  usually  leads  to  obesity.  Around  90%
of  type  II  diabetes  is  attributable  to  overweightness  and  to
the  metabolic  syndrome.  This  number  is  also  expected  to
increase  to  420  million  by  the  year  2025.5 In  addition,  the
human  and  financial  costs  of  DM  are also  on  the rise.6
A  similar  situation  occurs  in Peru,  where  TIIDM  preva-
lence  (TIIDM)  ranges  from  1 to  8%,  Lima  and  Piura  being the
most  affected  regions.7 In  conclusion,  DM is  a  health  problem
around  the  world,  one  that  is  threatening  to  reach pandemic
levels  by  2030,  with  alarming  increases  of  TIIDM  among  chil-
dren  and  with  potentially  devastating  consequences.5
DM  is  associated  with  an  increase  in risk  of premature
death;  thus,  every  year almost  4  million  deaths  are  caused
directly  by  this disease.  80%  of these  occur in underdevel-
oped  countries,  constituting  6.8%  of  overall  mortality.8
DM  diagnostic  methods  are:  random  glucose  test
>200  mg/dl  over  clinical  symptoms,  fasting  plasma  glucose
test  >126  mg/dl,  oral  glucose  tolerance  test  (OGTT)  after a
fast,  and  glycosylated  hemoglobin  test  A1c  ≥  6.5%  (Table  2).9
The  test  most  frequently  used is  the  OGTT,  used  in clinical
practice  for glycemic  and insulin  diagnoses.10--12 Moreover,
Table  1  Classification  of  DM.9
I.  Type  1  diabetes
A. Immune-mediated
B. Idiopathic
II. Type  2 diabetes
III.  Other  specific  types
A.  Genetic  defects  of  -cell  function
B.  Genetic  defects  in insulin  action
C. Diseases  of  the  exocrine  pancreas
D.  Endocrinopathies
E. Drug-  or  chemical-induced
F.  Infections
G.  Uncommon  forms  of  immune-mediated  diabetes
H. Other  genetic  syndromes  sometimes  associated  with
diabetes
IV. GDM
Table  2  Diagnostic  criteria  for  DM.9
1.  AlC  ≥  6.5%.  The  test  should  be  performed  in  a  laboratory
using  a  method  that  is NGSP  certified  and  standardized  to
the DCCT assay.a
OR
2.  FPG  ≥ 126  mg/dl  (7.0  mmol/l).  Fasting  is defined  as  no
caloric intake  for  at  least  8 h.a
OR
3.  2-h  plasma  glucose  ≥ 200 mg/dl  (11.1  mmol/l)  during  an
OGTT.  The  test  should  be  performed  as  described  by  the
World  Health  Organization,  using  a glucose  load
containing  the  equivalent  of  75  g anhydrous  glucose
dissolved  in water.a
OR
4.  In  a  patient  with  classic  symptoms  of  hyperglycemia  or
hyperglycemic  crisis,  a  random  plasma
glucose  ≥  200  mg/dl  (11.1  mmol/l).
a In the ansence of unequivocal hyperglycemia, criteria 1--3
should be confirmed by repeat testing.
it is the  most  sensitive  method  for  the  diagnosis  of  DM
within  the fasting  glycemic  test,  although  it requires  char-
acteristics  for  its  implementation,  such  as  fasting  basal
glycemia  <  110  mg/dl,  doses  of  75  g anhydrous  glucose  in
adults  or  1.75  g/kg  for  children,  performance  in the morn-
ing after  a  10--16  h fast,  the duration  of  the  test  is 180  min,
etc.13 One  of  the main  disadvantages  of  OGTT  is  its  repro-
ducibility,  thus it  is  recommended  to  have  at least  2  patho-
logical  OGTTs  when basal  glycemia  is  under  110  mg/dl.14
Moreover,  inter-individual  variabilities  have  been
described  according  to  glucose  metabolism,  which  generate
slants  in the interpretation  of  clinical  criteria  that  ought  to
be  estimated.  According  to  Clinical  Laboratory  Standards
Institute  (CLSI),  the resultant  parameters  of  OGTT  should
be  assessed  as  the  area under  the  curve  of  glucose  (AUCG)
and  insulin  (AUCI)  basal  indexes,  the maximum  allowable
error,  among  others,  mainly  to  determine  the sensitivity  to
peripheral  insulin.9,15--18 After  an  oral  glycemia  overload,
the  increase  in glycemia  does  not depend  solely  on  glucose.
There  are also  intestinal  hormones  involved,  the speed
of  gastric  emptying  and  the composition  of the  intake.
Thus,  tolerance  to  glucose  and  sensitivity  to  insulin  are
different  concepts,  making  the indexes  of  correction  and
evaluation  of  glycemic  sensitivity  necessary  to  guarantee
the quality  of the results  and  explain  the  recurrence  of
these  phenomena.18
Having  said  that, the  objective  of this  study  was  to  eval-
uate  the  criteria  for interpretation  of  OGTT  in the  Hospital
Nacional  Docente  Madre-Nin˜o  ‘‘San  Bartolomé’’  (HONADO-
MANI  SB)  in Lima,  Peru,  and  determine  the percentages
of  pre-diabetic  patients,  those  who  should  not have  been
included  within  the test  (basal  glucose  >  110  mg/dl)  and
those  who  presented  alterations  in the  curve of glucose
during  biochemical  determinations.
Materials and method
A non-experimental,  prospective  cross-sectional  analytic
study  was  conducted.
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Population  and sample
Population
The  population  consisted  of all  ambulatory  patients  referred
to  us by  agreement,  at HONADOMANI  SB.
Sample
Blood  samples  referred  from  outpatient  clinics  indepen-
dently  from  the Department  of  Help  to  diagnosis  at
the  Biochemistry  Department  for  glycemia  determination
though  OGTT,  which  complies  with  the  quality  criteria
according  to  CLSI Guide  POCT12-A3,  the ADA’s  guidelines
and the  recommendations  for  the laboratory  analysis  of
DM  diagnosis  and  management  and  the standardized  oper-
ational  procedures  --  SOP  --  of  the health center.19,20 These
are  selected  respecting  the following  previously  established
criteria  of  inclusion  and  exclusion.
Inclusion  criteria.  Patients  (male  and  female)  in a fasting
state  of  at  least  10  h,  ages  ranging  from  18  to  65  years
of  age,  stable,  without  a stress  condition,  pharmaceutical
consumption,  or  debilitating  situations  like  surgery.  Also,
patients  were  required  to  complete  the test  (180  min,  3
blood  collections)  post-glycemic  overload.  The  collection  of
samples  must  comply  with  the  quality  guidelines  previously
mentioned.
Exclusion  criteria.  Patients  who  did not  comply  with  the
fasting  state  of  at least  10  h.  Patients  outside  the  age
range  (19--65 years  old).  Patients  who  were  suffering  from
a  debilitating  or  oncological  situation,  or  undergoing  phar-
macological  therapies.  Those  patients  who  left the  test  or
complicated  blood  collections.  Those  samples  which were
collected  without  following  the  quality  and  normativity
criteria  of  CLSI  or  ADA,  in addition  to  samples  which were
clearly  contaminated.
Data  collection  techniques  and  sample  processing
Pre-analytic  stage
The  collection  was  conducted  in  the  Phlebotomy  area  of
the  HONADOMANI  SB  between  6  am  and  9  am,  using  BD
Vacutainer® (Franklin  Lakes,  New  Jersey,  USA)  of  3  ml,  with
a  red  cap  which  was  mixed  by  inversion  of  8--10  times,
according  to  the CLSI H03-A6  guide.  In order  to  achieve  this,
patients  must  have  remained  fasting  for  at least  10 h  prior
to the  collection,  with  a  payment  slip  from  the previous  day
of the  test,  and  with  a lemon  and  a disposable  cup.21
The  first  sample  (basal)  was  used to  evaluate  the admis-
sion of  patients  to  the test, excluding  those  who  were
above  100 mg/dl.  Subsequently,  they  were overloaded  with
oral  glucose  (anhydride  preparation:  ‘‘lemonade’’)  using the
following  formula;  75  g of  anhydride  glucose  for  adults  or
1.75  g/kg  for  children.  The  patient  was  monitored  for  the
whole  duration  of  the  test  (180  min).  The  samples  were
collected  at 60  and  180  min after  the glycemic  overload.
Conventional  cohort  values  were used  at >200  mg/dl  for
diabetics  and those  indicated  by  the  World  Health  Organi-
zation  (WHO)  for  the  diagnosis  of pre-diabetic  patients  of
100--199  mg/dl  (impaired  glucose  tolerance).22--24
Analytic  stage
The  processing  in the  clinical  lab  was  conducted  follow-
ing  the algorithm  established  by  the hospital  for  OGTT.
This  includes  the  reception  and  registration  of  the  sam-
ple  through  the standardized  code  and its  processing  within
120  min after the  sample  was  drawn.  The  biochemical
processing  was  conducted  through  the  Biochemical  Biosys-
tems  A25  auto-analyzer  (Pennsylvania,  USA),  which  has  a
daily  and historic  registry  of biochemical  analyses.  The
method  employed  for  the  determination  of glucose  was  glu-
cose  oxidase-peroxidase  through  the  glucose  activity  test
Trinder.25
Post-analytic  stage
Undetermined  results  or  those  which  were  outside  the  lin-
earity  of  the  trial were  repeated  and/or  diluted.  The  results
validated  by  Medical  Technologists  were  inputted  into  the
integrated  health  system  --  SIGOS  --  to  inform  patients  within
the  stipulated  times.
Data  analysis  technique
Data  analysis  was  performed  in  three  basic  processes:
codification,  from  the Biochemical  Biosystems  A25  auto-
analyzer’s  historical  registries  system; tabulation,  statistical
verification  and  the creation  of  charts  and  tables  using the
statistical  analyzer  SPSS  20.0  and  Microsoft  Office  Excel  2010
for  Windows.  The  evaluation  of  the distribution  of variables
was  conducted  using KMO  and  Bartlett’s  test  of sphericity,
resulting  in  a  matrix  of  correlations  between  adequate varia-
bles  (p  =  <0.05).
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Figure  1  Results  of  1271  samplings  of  glycemia  in the  HONADOMANI  SB.  Also,  the  proportion  of  diabetic  (glycemia  at  2 h  >200  mg/dl)
and pre-diabetic  (glycemia  at  2  h  between  110  and 199  mg/dl)  patients  diagnosed  through  the  OGTT.
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Ethics
Within  the  diabetic  ethics  framework,  the safeguarding,
reliability  and  irreplaceable  value  of  the  obtained  informa-
tion  will  only be  used for  the  purposes  of this study. This
research  has  the approval  of the  Department  of  Teaching  and
Aid  for  Research  and  the Ethics  and  Research  Commission  of
the  HONADOMANI  SB  (Reg.  78-2015).
Limitations
Several  limitations  should  be  taking  into  account  before
interpreting  the results.
First,  the biochemical  auto-analyzer  informatics  reg-
istry  does  not have  detailed  registries  or  information  of
the  selected  patients,  such as  age,  gender,  attributable
risk  factors,  physiological  condition,  diseases,  demo-
graphic  characteristics  and  family  history,  etc.  Second,
the  determination  of  glycemia  varies  considerably  between
demographics  and  age  groups.  Thus,  the pre-diabetic  and
diabetic  prevalence  rates encountered  are  not  transposed
toward  the  general  population  of  Peru.  Third,  the  OGTT
results  could  not  be  compared  to  the standard  refer-
ence  tests  like  Hb1Ac,  to  determine  its  variability  and
inaccuracy.26 Lastly,  the biochemical  processing  was  per-
formed  under  an  internal  and  external  quality  control;
however,  without  a quality  responsible  planning.
Despite  these  limitations,  our  research  is  the first  to  eval-
uate  the  resultant  parameters  of the  OGTT.
Results
From  the  conducted  research,  1.97%  of  patients  were
diabetic,  13.85%  were  pre-diabetic,  6.45%  produced  the
‘‘LowJump’’  (LJ)  glucose  reduction-rise  phenomenon  (alter-
ation  of  the  glucose  curve  post-oral  overload  which tends
to  reduce  the  concentration  of  plasma  glucose  in its  deter-
mination  at 60 min  and  returns  to  relatively  superior  levels
to  the  basal  concentration  at  180 min),  and  5.19%  of  the
patients  should  not  have  been  included  in the  study  due
to  the  fact that they  did  not  have  over  110 mg/dl  of  basal
glucose  (p  = <0.05)  (Fig.  1).11,27
Discussion
The  evaluation  of  OGTT  interpretation  criteria  exposes  an
elevated  rate  of  pre-diabetic  patients  and  a reduced  rate
of  diabetics,  which in conjunction  constitute  15.8%  of  the
prevalence  (Fig.  2).
The  prevalence  of  diabetic  patients  determined  in this
research  was  half  of  that communicated  in the  last  report
of  DM  prevalence  in  Lima  and Callao,  Peru  (3.9%).28 The
prevalence  rate  discovered  is  somewhat  similar  to  urban
averages  in  populations  over  3000  asl.  (Huaraz  --  1.3%).23
DM  is  a  chronic,  degenerative,  progressive  but  manageable
disease.  It  has  a  great  impact  on  the economy  of  the health-
care  system.  It  requires  serious  control  and a reasonable
stratification  of its  systemic  complications.
In the  same  way,  the proportion  of  patients  who  were
pre-diabetic  or  had  a  high  risk  of  diabetes  or  glucose
intolerance  was  13.85%;  prevalence  within  the  regional
average  is between  5  and  15%.29 Glucose  intolerance  is
a  risk  factor  for the development  of  TIIDM  and  implies  a
13.85%
1.97%
Diabetic
Prediabetics
Figure  2 Percentages  of  pre-diabetic  and  diabetic  patients.
The  radial  distribution  of  patients  wrongly  included  in the  test
is shown  in Fig. 3, highlighting  the  values  of  the second  glycemia
sampling  in comparison  to  the  first  and  the  third.
high  cardiovascular  risk.30,31 In  our  country,  the reported
prevalence  is  up to  90.8%  in  patients  who  are 50  years
and  older,  a  highly  elevated  prevalence,  suggesting  the
immediate  prioritization  of  health  care  attention  in order
to  avoid  future  complications.32
The  progression  from  normoglycemia  to  diabetes  may
take  several  years,  which  involves  intermediate  stages  of
dysglycemia.  This  atero-thrombogenic  alteration  becomes
evident  with  the alteration  of  glucose  when  fasting,
emergence  of  glycated  proteins  and progressively  cel-
lular  hypofunction,  increasing  the risk  of  morbidity  in
patients.33,34 Thus,  diabetes  indicates  a  decrease  in the
pancreatic  reserve  (up  to  50%  when there  is  no  diabetic
manifestation),  this  previous  metabolic  stage  is  evident  by
glycemia  between  100  and  199  mg/dl  by  the OGTT,  which
serves  as  a red  flag  to  avoid  its progression  to  DM.24 Inter-
vention  in  pre-diabetic  patients  is  an  efficient  strategy,  since
it  avoids  or  slows  down  the progressive  deterioration  of
the pancreas.  This  strategy  includes  an efficient  diagnosis,
modification  in lifestyles,  body weight  management,  ranges
from  45  to  65%  of  daily  energetic  intake,  physical  exercise,
pharmacological  treatment,  detection  algorithms,  etc.18 In
this  manner,  it is  demonstrated  and confirmed  that  the con-
trol  of  glycemia  is  an effective  measure  to  reduce  the  load
of  microvascular  and cardiovascular  complications,  such as
retinopathy,  nephropathy  and  neuropathy  in patients  with
TIDM  as  well  as  TIIDM.35--37
The  main  complication  in the  misguided  selection  of
patients  for  OGTT  is  the dizzy  feeling  and loss  of con-
sciousness  during  the glycemic  overload.  We found that
5.19%  of  patients  should  not  have  been  included  in the
test  (Fig.  3).  It  may  be a  minimum  finding,  however,  it
is  of relevance  given  the fact that  the lab  procedures
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Figure  3  Radial  distribution  of  patients  wrongly  included  in the  OGTT.  Observe  the  elevated  values  in the  second  sampling  (red
line/thicker line).  Glycemic  concentration  is  expressed  in mg/dl.  (For  interpretation  of  the  references  to  color  in  this  figure  legend,
the reader  is  referred  to  the  web  version  of  this  article.)
are standardized,  and  follow  internationally  established
flowcharts  which  rule  under  a  quality  control  system.  More-
over,  the  diagnosis  of over  half  of  these  patients  was
dysglycemia  (3.2%),  1.5% were  diabetics  and  only  0.5%  were
healthy  patients.9,11,12,15,16 Considering  that,  these  mistakes
in  patient  selection  are  a  result  of the generally  poor  knowl-
edge  of  the personnel  on  these  investigations,  work  over-
load,  or  the  fact that  there  is  no  other  diagnostic  method.
Thus,  the  modification  of  inclusion  criteria  of  patients  in
the  OGTT,  POE,  should  be  considered  and  rely on  the CLSI
POCT12-A,  Clinical  Laboratory  Improvement  Amendments,
(CLIA),  ADA  guidelines,  etc.  Also,  the  use  of  other  diagnos-
tic  methods  (i.e.  the A1c  Glycosylated  Hemoglobin  test),
evaluating  their  sensitivity,  disadvantages  and costs.
Lastly,  we  reaffirm  the importance  of  the  LJ  phenomenon
in  the  interpretation  of  the  OGTT,  because  it could  interfere
in  the  final  results.  From  the  final  reports  of  this phe-
nomenon  1.2%  were  dysglycemic  in ranges  of  100--175  mg/dl
(Fig.  1),  which  leads  us to  consider  its  involvement  in the
development  of the trial  and interferences  with  glycemia
--  increasing  it or  reducing it --  generating  undetermined
results,  or  even  worse,  false results.24
This  finding  proves  the  importance  of  inter-individual
biological  variability,  evident  by  the  events  through  which
it  may  occur,  like  different  physiological  conditions,
metabolism  of  the saturation  of  glycemia,  type of  anhydride
glucose,  population  group,  diabetics,  physiological  condi-
tions  where  typologies  of the individuals,  pre-diabetics,  or
other  non-clear  situations  occur.  Thus,  it  is  necessary  to
evaluate  its  reach  in interference,  to  establish  its total
allowable  error  and  understand  the biochemistry  and cel-
lular  behavior  during  the development  of  the test  among
individuals.
Furthermore,  a judicious  monitoring  is  required  in  order
to  understand  and  know  its  physiology  and the events
through  which  it  occurs,  corresponding  to  the  different
metabolisms  during the test and their  diagnostic  implica-
tions.  We  definitely  suggest  that  other  glycemia  tests  should
be  conducted  in a patient  where  this  phenomenon  is  discov-
ered,  (Hb1A1c,  etc.)  or  repeat  the  OGTT  twice.11
Diabetes  mellitus  is  a metabolic  disease  which  imposes  a
high  economic  and social  cost  around  the  world,  hence  its
prevention  and treatment  should  be  considered  imperative
in  health  and a priority  worldwide.  The  diagnosis  should  be
thoroughly  examined,  from  the  selection  of patients  to  the
determined  ranges  of  glucose  in each collection,  with  the
purpose  of  avoiding  undetermined  results  or false  negatives.
Funding
This  study  was  self-financed  by  the  authors.
Documento descargado de http://www.elsevier.es el 24-08-2016
152  J.J.  Moya-Salazar,  L.  Pio-Dávila
Conflict of  interest
The  authors  state  that  there  are no  conflicts  of  interests.
References
1. Rodbard HW, Blonde L,  Braithwaite SS, et al. American Associ-
ation of Clinical Endocrinologists medical guidelines for clinical
practice for the management of  diabetes mellitus. Endocr
Pract. 2007;13 Suppl. 1:1--68.
2. World Health Organization. Global status report on non-
communicable diseases 2010. Geneva: WHO; 2011.
3. International Diabetes Federation, IDF. Diabetes atlas 2012
update. 5th ed. Brussels: IDF; 2013.
4. Wild S,  Roglic G, Green A, Sicree R,  King H.  Global prevalence of
diabetes: estimates for the year 2000 and projections for 2030.
Diabetes Care. 2004;27:1047--53.
5. Hossain P, Kawar B, El Nahas M.  Obesity and diabetes in
the developing world: a growing challenge. N Engl J Med.
2007;356:213--5.
6. The world health report 2006: working together for health.
Geneva: World Health Organization; 2006.
7. García F, Solís J, Calderón J, et  al. Prevalencia de diabetes mel-
litus y factores de riesgo relacionados en una población urbana.
Rev Soc Per Med Interna. 2007;20:90--4.
8. Rawal RB, Tapp RJ, Williams ED, Chan C, Yasin S, Olden-
burg B. Prevention of type 2 diabetes and its complications
in developing countries: a review. Int J  Behav Med. 2012;19:
121--33.
9. American Diabetes Association. Diagnosis and classification of
diabetes mellitus. Diabetes Care. 2014;37 Suppl. 1:S81--90.
10. Matsuda M,  De Fronzo RA. Insulin sensitivity indices obtained
from oral glucose tolerance testing: comparison with the eug-
lycemic insulin clamp. Diabetes Care. 1999;22:1462--70.
11. Stumvoll M, Mitrakou A, Pimenta W, et  al. Use of  the oral glucose
tolerance test to assess insulin release and insulin sensitivity.
Diabetes Care. 2000;23:295--301.
12. Calvar CE, Bengolea SV, Hermes R, Loyato M. Critical evaluation
of the oral glucose tolerance test for the diagnosis of insulin
resistance in patients with polycystic ovary syndrome. Medicine
(Baltimore). 2007;67:2--6.
13. Puig-Domingo M, Leiva Hidalgo A. Diabetes mellitus: concepto,
clasificación y etiología. In: Casanueva Freijo F,  Vázquez García
JA, editors. Endocrinología clínica. Díaz De Santos Eds, vol. 14.
1995. p. 241--9.
14. McDonald GW, Fisher GF, Burnham C. Reproducibility of  the oral
glucose tolerance test. Diabetes. 1965;14:473--80.
15. Myllynen P, Koivisto V,  Nikkila E. Glucose in tolerance and
insulin resistance accompany immobilization. Acta Med Scand.
1987;222:75--81.
16. Matthews DR, Hosker JP, RudenskiAS, Naylor BA, Teacher DF,
Turner RC. Homeostasis model assessment: insulin resistance
and b-cell function from fasting plasma glucose and insulin
concentration in man. Diabetología. 1985;28:412--9.
17. Avignon A, Búgner C, Mariano-Goulart D, Colette C, Monnier L.
Assessment of insulin sensitivity from plasma insulin and glu-
cose in the fasting or post oral glucose-load state. Int J Obes.
1999;23:512--7.
18. Girbés BJ. Methods for the determination of insulin sensi-
tivity based on  an  oral glucose tolerance test. Av Diabetol.
2008;24:296--304.
19. Clinical Laboratory Standards Institute. Point-of-care blood glu-
cose testing in acute and chronic care facilities. Approv Guidel.
2013;33:14--26.
20. American Diabetes Association Guidelines. Recommendations
for laboratory analysis in the diagnosis and management of dia-
betes mellitus. Diabetes Care. 2011;34:e62--84.
21. Clinical and Laboratory Standards Institute. H3-A6. Procedures
for the collection of diagnosis blood specimens by venipuncture;
2007. p.  27.
22. American Diabetes Association. Screening for type 2 diabetes.
Diabetes Care. 2004;27 Suppl. 1:S11--4.
23. Pan American Health Organization. Guías ALAD de diagnóstico
control y tratamiento de la diabetes mellitus tipo  2, vol. 3;
2006. p.  12--7.
24. American Diabetes Association. Standards of  medical care in
diabetes -- 2014. Diabetes Care. 2014;37 Suppl. 1:S14--20.
25. Trinder P. Determination of blood glucose using an
oxidase--peroxidase system with a non-carcinogenic
chromogenic. J Clin Pathol. 1969;22:158--61.
26. American Diabetes Association. Translating the A1C assay
into estimated average glucose values. Diabetes Care.
2008;31:1473--8.
27. Amatuzio DS, Stutzman LF, Vanderbilt JM, Nesbitt S. Inter-
pretation of  the rapid intravenous glucose tolerance test in
normal individuals and in mild diabetes mellitus. J  Clin Investig.
1953;32:428--35.
28. Revilla L,  López T, Sánchez S, Yasuda M,  Sanjinés G.  Prevalence
of hypertension and diabetes in residents from lima and Callao,
Peru. Rev Peru Med Exp Salud Publica. 2014;31:437--44.
29. Qiao Q, Lindström J, Valle TT, Tuomilehto J. Progression to
clinically diagnosed and treated diabetes from impaired glu-
cose tolerance and impaired fasting glycaemia. Diabet Med.
2003;20:1027--33.
30. Levitzky YS, Pencina MJ, D’Agostino RB, et  al. Impact of
impaired fasting glucose on cardiovascular disease: the Fra-
mingham Heart Study. J Am Coll Cardiol. 2008;51:264--70.
31. Vargas-Ancona L. Epidemiologia de la diabetes mellitus, intoler-
ancia a la  glucosa y factores de riesgo aterogénico en Yucatán,
México. Rev Biomed. 1994;5:151--9.
32. Figueroa ML.  Diagnóstico de Intolerancia a la glucosa en
pacientes mayores de 50 An˜os, en el  servicio de laboratorio
del Hospital Suárez Angamos II -- Es Salud Lima-Perú. Rev  Méd.
2011;1:72--7.
33. Flores JA, Díaz A, Trevin˜o S,  Brambila EM. The effects of  a hyper-
caloric diet on the development of  dysglycemia and dyslipemia
its impact on the kidney cytoarchitecture. Mensaje Bioquímico.
2014;61:165--74.
34. Clement S,  Braithwaite SS, Magee MF, et al.  Management of
diabetes and hyperglycemia in hospitals, American Diabetes
Association. Diabetes Care. 2004;27:553--91.
35. The DCCT Research Group. Diabetes control and complications
trial (DCCT): results of  feasibility study. Diabetes Care.
1987;10:1--19.
36. Intensive blood-glucose control with sulphonylureas or
insulin compared with conventional treatment and risk of
complications in patients with type 2 diabetes. Lancet.
1998;352(9131):837--53.
37. Ohkubo Y, Kishikawa H, Araki E, et  al. Intensive insulin
therapy prevents the progression of diabetic microvascular
complications in Japanese patients with non-insulin-dependent
diabetes mellitus: a randomized prospective 6-year study. Dia-
betes Res Clin Pract. 1995;28:103--17.
Documento descargado de http://www.elsevier.es el 24-08-2016
